Location: Hyatt Regency Boston Harbour
Cellistic is pleased to participate as a Hosting Partner at the iPSC Drug Development Summit, where our team will join fellow leaders across the field to address the technical and manufacturing challenges that will determine the future of iPSC-based therapies.
With two delegates attending on site and our CTO, Stefan Braam, joining the panel discussion, "Scaling Up iPSC Manufacturing to Commercial Volumes to Enable Larger Patient Populations Without Quality Trade-Offs," Cellistic will contribute to the Process Development & CMC conversation around one of the sector's most pressing priorities: delivering scalable iPSC manufacturing without sacrificing quality, consistency, or patient reach.
As iPSC-derived therapies advance toward broader clinical and commercial application, manufacturing strategy has become a key differentiator. Cellistic is committed to enabling robust, scalable approaches that support process reproducibility, product quality, and long-term manufacturability across larger patient populations.
We look forward to engaging with peers across the summit on the evolving CMC, process development, and scale-up requirements that will shape the next generation of iPSC therapeutics.
Meet the team
-
Stefan Braam - Chief Technical Officer
-
Wesley Tidball - Senior Director, Business Development North America - East & Europe